ClinicalTrials.gg
RecruitingNCT06345495Updated Sep 16, 2026

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

A Phase 2 interventional study of Ruxolitinib and Allogeneic Stem Cell Transplantation in Splenomegaly and Myelofibrosis, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by M.D. Anderson Cancer Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Splenomegaly with a site in United States — 4 open to participants now, 6 under way, 1 of them phase 3. Splenomegaly · United States.

Planned enrollment
7th of 16
30 · median 26
Started
2024
the only one that year
Phase 2
6 of 20
1 open now
Registered
19th of 20
by date
Lead sponsor
4 of 20
M.D. Anderson Cancer Center

Among the 20 studies in Splenomegaly with a site in United States, this one is the 7th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2024, is one of 6 in phase 2, and was the 19th registered.

Splenomegaly

43 studies on the registry are indexed under Splenomegaly; 9 are open to participants now.

Browse Splenomegaly studies →

Open to participants now

4 of the 20 studies in Splenomegaly with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Splenomegaly studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Splenomegaly with a site in United States, or all of them as a file.
02

Study summary

To learn if giving ruxolitinib and busulfan before a stem cell transplant can help to reduce spleen size and help the transplant to succeed.

Read the detailed description

Primary Objective

1) Compare the proportion of patients alive, disease free, engrafted, and without poor graft function at 100 days post-transplant with the historical rate of 45%.

Secondary Objectives:

  1. Overall survival
  2. Progression-free survival
  3. Graft vs host disease relapse free survival
  4. Relapse rate
  5. Non-relapse Mortality
  6. Time to Neutrophil and platelet engraftment
  7. Time to red cell transfusion independence
  8. Graft failure
  9. Acute and chronic GVHD
  10. Grade 3 -5 Toxicity
  11. Incidence of poor graft function5
  12. Need for growth factors (myeloid or thrombopoietic) at 100 days
  13. Spleen response around day -7, -1, 30, and 100 days
  14. Need for transfusions at 100 days
  15. Time to discontinuation of immunosuppressives

Exploratory Objectives:

  1. Immune reconstitution
  2. Cytokine profile
03

Conditions studied

  • Splenomegaly
  • Myelofibrosis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants 18 years to less than or equal to 75 years.
  2. Able to provide written consent.
  3. Primary or secondary Myelofibrosis (may have received Jak inhibitors including ruxolitinib)
  4. Enlarged spleen by palpation or imaging. For the purpose of this study, splenomegaly is defined as any clinically palpable spleen or spleen larger than 12 cms on imaging.
  5. Has a fully matched (8/8:HLA A, B, C, DRB1) related or matched unrelated donor.
  6. Adequate renal function, including:

    a. Serum creatinine \</= 1.5 mg/dL or estimated (eGFR using the CKI-EPI equation) >/= 40 ml/min/1.73 m2.

  7. Adequate liver function, including:

    1. /AST \</= 3 x
    2. Direct \</= 1mg/dL
    3. No history of liver cirrhosis. No ascites.
  8. Female participants of must have negative results for a serum pregnancy test. Female participants must agree to not breastfeed during the study and for 3 months post-completion of the study therapy.
  9. Subjects who are of childbearing potential, sexually active, and at risk of pregnancy must agree to use a highly effective method of for the duration of the active treatment and at least 3 months post-completion of the study therapy. Highly effective methods of contraception include the following:

    1. Hormonal contraception (i.e., birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
    2. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of study agent administration. Men who are able to have children must use effective birth control while on the study. If the male participant fathers a child or suspects that he has fathered a child while on the study, he must immediately notify his doctor.

Exclusion criteria

Exclusion Criteria:

  1. Positive beta HCG in females of defined as not for 24 months or no previous surgical sterilization or lactating females.
  2. \<40%
  3. Corrected DLCO \< 50%
  4. Evidence of other uncontrolled condition(s) including, but not limited to:

    1. Uncontrolled and/or active systemic infection (viral, bacterial or fungal)
    2. Active virus (HBV), (HCV), or TB infection or requiring treatment for the same.
    3. Thrombosis including MI, Stroke, PE, DVT in the past 6 months

Note: subjects with serologic evidence of prior vaccination to HBV (i.e. hepatitis B surface (HBs) antigen negative-, anti-HBs antibody positive and anti-hepatitis B core (HBc) antibody negative) or positive anti-HBc antibody from intravenous immunoglobulins (IVIG) may participate.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Ruxolitinib and Allogeneic Stem Cell Transplantation

    Participants will be asked to receive study drugs and a stem cell transplant and attend study visits, at which various tests and procedures will be performed. Participants are expected to receive treatment for about 100 days, followed by a year of follow-up.

    Drug: Ruxolitinib · Procedure: Allogeneic Stem Cell Transplantation · Drug: Levetiracetam · Drug: Eltrombopag · Drug: Busulfan · Drug: Romiplostim · Drug: Fludarabine phosphate · Drug: Cyclophosphamide · Drug: Mesna · Drug: Tacrolimus

Interventions

  • Given by PO

    Also known as: Jakafi, INCB018424, INC424

  • ProcedureAllogeneic Stem Cell Transplantation

    Given by Transplant

    Also known as: Autologous stem cell transplant, Cord Blood

  • Given by PO

  • Given by PO

    Also known as: Promacta®

  • Given by IV

    Also known as: Busulfex™, Myleran®

  • Given by IV

    Also known as: AMG 531, Nplate

  • Given by IV

    Also known as: Fludarabine, Fludara®

  • Given by IV

    Also known as: Cytoxan®, Neosar®

  • DrugMesna

    Given by IV

    Also known as: Mesnex™

  • Given by IV or PO

    Also known as: Prograf®

06

What researchers measure

Primary outcomes

  1. Safety and adverse events (AEs)

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

    Time frame: Through study completion; an average of 1 year.

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Jan 2027, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2024
First posted
Apr 3, 2024
StartActual
Oct 1, 2024
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2029
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06345495
Collaborators
Incyte Corporation
Responsible party
Sponsor
First posted
Apr 3, 2024
Start date
Oct 1, 2024
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2029 (estimated)
Last update
Sep 16, 2026

Study contacts

Uday Popat, MD
Contact
upopat@mdanderson.org
(713) 563-0812
Uday Popat, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion